Member Info for BlahBlahDoh

Don't understand the point of you posts mk, they are obviously unattributed and undated quotes from somewhere, but no new information. Pru and M&G are in similar positions, the only difference is that insurance companies are facing specific pressure to retain dividends, but all financial companies face that pressure to some extent, and whether either company will cancel is still up for debate, imo.

Imagination were sold years ago and it seems a bit late to worry about the Chinese taking over the board. What did they expect would happen? I would imagine any IP was transferred to China long ago, regardless of "ownership". I don't know if it is still the case, but Imagination used to own MIPS technology too, which was used by US defence companies. Not sure how it affects Nanoco though, because no Chinese company has showed any interest in them.

"Some media outlets, including Daily Mail and RT, promoted a video that showed a young Chinese woman eating a bat and suggested it was shot in Wuhan, but later it was confirmed that the footage was filmed by travel vlogger Wang Mengyun in the island country of Palau in 2016, to showcase local cuisine." (Wikipedia)

https://www.eater.com/2020/1/31/21117076/coronavirus-incites-racism-against-chinese-people-and-their-diets-wuhan-market

Terrific performance in Q1, everything good, revenue up, orders up, China back to work, Vietnam unaffected, yet the Q4 dividend has been clawed back due to uncertainty over the outlook ahead. Seems like an overabundance of caution given the numbers, but this management have proven to be pretty canny, and better safe than sorry. Where shareholders lose out in dividends they may gain in SP. Pretty dire outlook for some other companies if even booming XPP see a problematic near future, presumably worried about purchasers going bust or contracting.

"COVID-19 creates a high level of uncertainty about the Group’s performance in the balance of the year. To date, order intake has remained robust and the Group has a substantial backlog to fulfil, with shipments weighted towards the second half. While we remain encouraged by the strength of our order book, the extent of disruption to the global economy from the impact of COVID-19 is currently impossible to predict, introducing a significant element of uncertainty into the outlook for 2020 as a whole. "

Another encouraging update, and it sounds like MrCHIPS was in harmony with management thinking, they have adapted well to the funeral march: New Orleans style rather than Chopin.

Lloyds were more or less ordered to cancel their dividend, along with other lenders. M&G are in a different position.
Like Spikey said, it looks bad from a P.R. point of view to be "giving" money to "rich" shareholders when most people are financially challenged and jobs are at risk, so that will be a consideration. They are probably very reluctant to change their plans though, and I still think there is a good chance it will be paid, or at worst a postponement rather than cancellation.
Possibly best to leave it for a last minute decision: things could easily look very different in a week or two.

This was (obviously?) a joke:
"April Fools day has been officially banned under COVID-19 emergency measures, in order to prevent inadvertent contamination and to prevent panic spreading due to hoaxes."
Anyone fooled?

Actually April Fools day has been officially banned under COVID-19 emergency measures, in order to prevent inadvertent contamination and to prevent panic spreading due to hoaxes.

Despite the latest downwards plunge on the Roller-COVID-ster, M&G are not "one of the biggest fallers in the ftse 100 " this time: https://www.hl.co.uk/shares/stock-market-summary/ftse-100/heat-map

"M&G, Phoenix Group, Standard Life Aberdeen and Legal & General were all moving higher as well.

To take note of, back on 10 January analysts at JP Morgan had told clients that the former of those was trading at an unjustified discount to its peers."

https://www.lse.co.uk/news/MNG/ftse-100-movers-air-travel-stocks-insurers-pace-gains-qyrjhf6cl4uka82.html

Unusual. John Joseph Danilovich bought a quarter million dollars worth. Other directors not biting yet, even at these levels.

Perhaps we should be thinking "if" rather than "when" a vaccine is developed? No vaccine is available for SARS even now, after years of trying, suggesting it may be much more difficult than some people think. Despite the unprecedented worldwide drama, much of the funding for development of vaccines for SARS-CoV-2 still seems to be coming mainly from a single charity. Big business continues to neglect virology generally, presumably for financial reasons, and that is probably why ORPH's share price has remained anchored despite the delusional enthusiasm of many newcomers here.

Flu-v has more chance of generating licensing fees than a lottery ticket has of winning big, but it's far from certain, and virology generally shouldn't be the main reason for investing here unless you think a change in attitude from policy makers and big investors is likely. Fortunately there are other compelling reasons, although they are now probably longer term than initially envisaged.

Change the title of the thread to 'ventilator'?
Good luck in the bunkers everyone. Endure.

Interesting snippet from the Mike Wells RNS today:

"the Board is ensuring that, alongside preparations for a minority IPO, it continues to actively evaluate other options in relation to Jackson"

Translation: In your face, Loeb, you ain't the boss of me!

Thanks BillB, glad you like the username, and it seems lot's of people are happy you noticed it. Maybe it'll go "viral"! No refutation of any of the points I made makes for a poor discussion though, and suggests you (and they) have no real argument, just disapproval?

ORPH's chances of three-bagging, as Cathal hoped, have probably diminished as any potential purchasers are likely to be conserving cash for the foreseeable future. Temporary demand for services should make his task of turning around the businesses easier in the short term, so the valuation might see a modest increase, but once the crisis has lost it's urgency, maybe by the end of the year, firms like Novacyt and ORPH will probably see a corresponding decline in prospects, especially if a vaccine is well advanced by then. The economy could conceivably take a generation to recover, possibly similar to a post-war scenario. Perhaps targeting long-term international and public funding for general virology studies is the best way forward to capitalise on the companies strengths as an ongoing concern, and the planned exit may have to be delayed?

This popular obsession with positivity, and aversion to anything else, is as unhealthy as eating too much sugar, or hollywood movies where the hero is always American and the ending is always happy.

Discussing possible applications of Nanoco IP has been done to death, long before most of the current posters arrived, but the company have failed really, really badly at the two most promising of those applications and the most positive thing to do would be to face up to that reality, rather than suppressing it and concentrating on distracting irrelevancies about the shopworn "potential".

Current management have consistently failed to hit their own stated targets, whether it be selling material or selling the company, therefore positive posts are inappropriate and, arguably, misleading. Let's be positive when they do something successful, or get sacked.

Indeed Spikey, they continue to invest heavily in Thailand - business as usual!
Whisper it quietly, but is the market on the turn? M&G looks rubbery.

Hm 20,000 volunteers at £3,500 each. That adds up to £70m. Wonder what's really happening.

The science of serology measures antibodies in the bloodstream to detect immunity. Public Health England are working on one for COVID-19 and according to Professor Sir Mark Walport, who ought to be "in the know", they are close to one: https://www.itv.com/news/2020-03-19/uk-very-close-coronavirus-test-to-reveal-who-has-had-covid-19-with-no-symptoms/